… derivatives of benzochalcone as selective CYP1B1 inhibitors. The optimized derivatives
were … This research could provide a suitable starting point for the development of more potent …

… of the anti-cancer agents and CYP1B1 inhibitors is suggested to … Benzochalcones (Figure
6) was another series of … safe CYP1B1 inhibitors is still a developing area of research. …

… Development of benzochalcone derivatives as selective CYP1B1 inhibitors and anticancer
agents. … Chalcones, inhibitors for topoisomerase I and cathepsin B and L, as potential …

… the CYP1B1 inhibitory activity. The results achieved in this study would lay a foundation for
future development of selective, … -expressing cells to some anticancer drugs. Apart from its …

… diverse anticancer drugs … CYP1B1 inhibitory potency, selectivity and water-soluble potential,
our attention was drawn to the development of pyridine substituted derivatives as CYP1B1 …

… deactivation of structurally diverse anticancer drugs, for example… suggests that the inhibition
of CYP1B1 is a potential strategy … successfully developed a kind of potent CYP1B1 inhibitors, …

… as potential anticancer agentsCitation 13 , we … growth and metastasis without obvious
toxicity. Taken together, this study provided a plausible anticancer mechanism of benzochalcone …

… of several commonly used anticancer drugs including docetaxel, paclitaxel and cisplatin, …
to the development of new CYP1B1 inhibitors for the treatment of anticancer drug resistance …

… Claisen-Schmidt condensation produced benzochalcone 12 in a … need for more efficient
anticancer agents and new strategies … for developing PROTACs molecules to sensitize CYP1B1-…

… from CYP1B1 overexpression in HEK293 and A2780 cells [14]. In 2019, Dong et al. reported
a series of benzochalcone derivatives as potent CYP1B1 inhibitors … to anticancer drugs [46]. …